[ad_1]
Summary
– Omeros transitions from a distressed microcap to a $1.1B+ small-cap following a transformative Novo Nordisk deal and FDA approval of YARTEMLEA.
– YARTEMLEA's U.S. peak annual sales are estimated at no more than $250 million, given the niche, fragmented TA-TMA market and entrenched…
[ad_2]